The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective - and more by some measures - than the original shot, the company said.

If coronavirus vaccines are restricted to seniors and those at high risk, parents of young children and relatives of medically vulnerable people face a higher bar for shots.